Biperiden (CHEM002277)

IdentificationTaxonomyBiological PropertiesPhysical PropertiesToxicity ProfileSpectraConcentrationsLinksReferencesTargets (5)XML
Record Information
Version1.0
Creation Date2009-07-21 20:27:42 UTC
Update Date2026-03-26 21:41:37 UTC
Accession NumberCHEM002277
Identification
Common NameBiperiden
ClassSmall Molecule
DescriptionA muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. [PubChem]
Contaminant Sources
  • HMDB Contaminants - Urine
  • STOFF IDENT Compounds
  • T3DB toxins
Contaminant Type
  • Amine
  • Antidyskinetic
  • Antiparkinson Agent
  • Drug
  • Metabolite
  • Muscarinic Antagonist
  • Organic Compound
  • Parasympatholytic
  • Synthetic Compound
Chemical Structure
Thumb
MOLSDFPDBSMILESInChI
Synonyms
ValueSource
1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-olChEBI
alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanolChEBI
alpha-Bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanolChEBI
BiperideneChEBI
BiperidenoChEBI
BiperidenumChEBI
AkinetonKegg
a-5-Norbornen-2-yl-a-phenyl-1-piperidinepropanolGenerator
Α-5-norbornen-2-yl-α-phenyl-1-piperidinepropanolGenerator
a-Bicyclo[2.2.1]hept-5-en-2-yl-a-phenyl-1-piperidinepropanolGenerator
Α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-1-piperidinepropanolGenerator
BeperidenHMDB
BiperidineHMDB
Biperiden, 1R-(1 alpha,2 alpha(r*),4 alpha)-isomerHMDB
Biperiden hydrochlorideHMDB
Biperiden, 1S-(1 alpha,2 alpha(r*),4 alpha)-isomerHMDB
Hydrochloride, biperidenHMDB
alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanolHMDB
Chemical FormulaC21H29NO
Average Molecular Mass311.461 g/mol
Monoisotopic Mass311.225 g/mol
CAS Registry Number514-65-8
IUPAC Name1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol
Traditional Namebiperiden
SMILESOC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
InChI IdentifierInChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
InChI KeyYSXKPIUOCJLQIE-UHFFFAOYSA-N
Chemical Taxonomy
Description belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
KingdomOrganic compounds
Super ClassOrganic nitrogen compounds
ClassOrganonitrogen compounds
Sub ClassAmines
Direct ParentAralkylamines
Alternative Parents
Substituents
  • Aralkylamine
  • Monocyclic benzene moiety
  • Piperidine
  • Benzenoid
  • 1,3-aminoalcohol
  • Tertiary alcohol
  • Tertiary amine
  • Tertiary aliphatic amine
  • Azacycle
  • Organoheterocyclic compound
  • Alcohol
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organopnictogen compound
  • Aromatic alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginExogenous
Cellular Locations
  • Membrane
Biofluid LocationsNot Available
Tissue LocationsNot Available
PathwaysNot Available
Applications
Biological Roles
Chemical RolesNot Available
Physical Properties
StateSolid
AppearanceWhite powder.
Experimental Properties
PropertyValue
Melting Point114°C
Boiling PointNot Available
Solubility25.1 mg/L
Predicted Properties
PropertyValueSource
Water Solubility0.0043 g/LALOGPS
logP4.28ALOGPS
logP3.54ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.82ChemAxon
pKa (Strongest Basic)9.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 ŲChemAxon
Rotatable Bond Count5ChemAxon
Refractivity97.02 m³·mol⁻¹ChemAxon
Polarizability36.74 ųChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash KeyView
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (1 TMS) - 70eV, Positivesplash10-0096-9261000000-a2bf53b32ad045169c69Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positivesplash10-054n-9520000000-3d69a8227dbbcbaa85a2Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, PositiveNot AvailableSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-01ox-1096000000-b99cc35f37f276338977Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0002-9040000000-0e1cce5acf474b6a379fSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-016r-9110000000-6c95e29e42a503874c09Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-03di-0019000000-15b9d0ad97ade514831cSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-03ec-9145000000-6475a16f5449091aedb6Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-001i-9000000000-7c0cf15c2c8f5071caf7Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-03di-4009000000-5d4593f5bf86b7105063Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0002-9002000000-91d2484c2b5c788ee347Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0002-9220000000-bd998e4698c9aaf6a99eSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-03di-0009000000-db992041ed33362f9a42Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-03di-1549000000-050f3e90417671bee316Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0a4i-1935000000-317f7afd162e7d4dca0bSpectrum
MSMass Spectrum (Electron Ionization)splash10-0002-9000000000-92eb93b999cf7f5ec519Spectrum
Toxicity Profile
Route of ExposureOral
Mechanism of ToxicityParkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance.
MetabolismThe metabolism of biperiden is not completely understood, but does involve hydroxylation.
Toxicity ValuesLD50=760 mg/kg (Orally in rats).
Lethal DoseNot Available
Carcinogenicity (IARC Classification)No indication of carcinogenicity to humans (not listed by IARC).
Uses/SourcesFor use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.
Minimum Risk LevelNot Available
Health EffectsNot Available
SymptomsSigns of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
TreatmentTreatment of acute overdose revolves around symptomatic and supportive therapy. If Biperiden was administered orally, gastric lavage or other measures to limit absorption should be instituted. A small dose of diazepam or a short acting barbiturate may be administered if CNS excitation is observed. Phenothiazines are contraindicated because the toxicity may be intensified due to their antimuscarinic action, causing coma. Respiratory support, artificial respiration or vasopressor agents may be necessary. Hyperpyrexia must be reversed, fluid volume replaced and acid-base balance maintained. Urinary catheterization may be necessary. Routine use of physostigmine for overdose is controversial. Delirium, hallucinations, coma, and supraventricular tachycardia (not ventricular tachycardias or conduction defects) seem to respond. If indicated, 1 mg (half this amount for the children or elderly) may be given intramuscularly or by slow intravenous infusion. If there is no response within 20 minutes, and additional 1 mg dose may be given; this may be repeated until a total of 4 mg has been administered, a reversal of the toxic effects occur or excessive cholinergic signs are seen. Frequent monitoring of clinical signs should be done. Since physostigmine is rapidly destroyed, additional injections may be required every one or two hours to maintain control. The relapse intervals tend to lengthen as the toxic anticholinergic agent is metabolized, so the patient should be carefully observed for 8 to 12 hours following the last relapse. (3)
Concentrations
Not Available
DrugBank IDDB00810
HMDB IDHMDB0014948
FooDB IDNot Available
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG IDNot Available
BioCyc IDNot Available
METLIN IDNot Available
PDB IDNot Available
Wikipedia LinkBiperiden
Chemspider ID2289
ChEBI ID3112
PubChem Compound ID2381
Kegg Compound IDC07941
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis Reference

Peter Klein, “Method for the production of biperiden II.” U.S. Patent US20040152899, issued August 05, 2004.

MSDSNot Available
General References
1. Nishiyama K, Mizuno T, Sakuta M, Kurisaki H: Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol. 1993;60:479-83.
2. https://www.ncbi.nlm.nih.gov/pubmed/?term=10877003
3. https://www.ncbi.nlm.nih.gov/pubmed/?term=12873507
4. https://www.ncbi.nlm.nih.gov/pubmed/?term=25160769
5. https://www.ncbi.nlm.nih.gov/pubmed/?term=25466702
6. https://www.ncbi.nlm.nih.gov/pubmed/?term=2579237
7. https://www.ncbi.nlm.nih.gov/pubmed/?term=26479221
8. https://www.ncbi.nlm.nih.gov/pubmed/?term=28216067